Supplements
For youBrowse allYour supplements
Ortho Molecular

OcuView

OcuView includes a unique blend of key nutrients, which have been shown to support healthy eye function and maintain the long-term health of the eyes.

$29.20$36.50save $7.30

Questions before you buy?

RTHM can read this product's full label and weigh it against your own records.

Free shipping
On orders over $150
Practitioner grade
Direct from the manufacturer
Member pricing
Up to 20% under retail

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Product insights

  • OcuView is designed to support eye health with a blend of key nutrients.
  • It contains antioxidants like vitamin C and alpha lipoic acid to neutralize free radicals.
  • The formula includes zinc biglycinate chelate, a highly absorbable form of zinc.
  • OcuView includes carotenoids, lutein and zeaxanthin, known to support the health of the macula.

Suggested use

From the manufacturer
2 capsules per day or as recommended by your health care professional.

What it supports

6 benefits
  • Supports healthy eye function
  • Maintains long-term health of the eyes
  • Protects the macula
  • Enhances visual acuity
  • Neutralizes free radicals
  • Prevents oxidative damage to delicate eye tissues

What's in it

Per serving
Ingredient
Amount
% Daily Value
Vitamin C (as Ascorbic Acid USP)
500 mg
**
Vitamin E (from 400 IU as d-Alpha Tocopherol Succinate USP)
268 mg
**
Zinc (as TRAACS® Zinc Bisglycinate Chelate)
25 mg
**
Alpha Lipoic Acid
100 mg
**
Lutein
10 mg
**
Zeaxanthin
2 mg
**

The research

2 cited studies
1.
National Eye Institute Clinical Trial

A ten-year clinical trial showed that high levels of antioxidants, carotenoids, and zinc reduced the risk of advanced age-related macular deterioration and associated vision loss by 25%.

2.
Five-Year Follow-Up Trial

Higher intakes of lutein and zeaxanthin were shown to provide increased macula protection and reduce the advancement of age-related macular deterioration by an additional 20%.